# Grand Pharmaceutical acquires 17.8% stake in InnovHeart and rights to Saturn device

Grand Pharmaceutical Group will acquire approximately 17.8% equity of InnovHeart and obtain exclusive rights to the Saturn mitral valve replacement device in Greater China for €43.8 million.

- Type: Acquisition
- Announced: 2021-11-28
- Value: $49.5M (43.8M EUR)
- Status: completed
- Products: Saturn mitral valve replacement device
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Grand Pharmaceutical Group](https://endata.com/companies/28076.md) (acquirer)
- [InnovHeart](https://endata.com/companies/59266.md) (target)

## Sources

- [grandpharm.com](https://www.grandpharm.com/en/news/gp-hk-introduces-a-global-innovative-mitral-valve-replacement-medical-device-saturn/), 2021-11-28: "The Group will acquire approximately 17.8% equity interests of InnovHeart and obtain the exclusive development, manufacturing and commercialization rights of Saturn"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.